世界の1型糖尿病治療薬市場の分析と予測

当レポートでは、世界の1型糖尿病治療薬市場について調査分析し、市場概要、市場決定要因、市場区分、競合情勢、地域別の分析、主要企業プロファイルなど、体系的な情報を提供しています。

第1章 レポートサマリー

第2章 市場概要と考察

• 定義
• アナリストの見解・現在の市場動向
• 規制

第3章 市場決定要因

• 促進要因
• 抑制要因
• 機会

第4章 市場区分

• インシュリン類似体別
• 薬剤分類別
• 装置別

第5章 競合情勢

• 戦略分析
• 主要企業分析

第6章 地域別の分析

• 北米
• 欧州
• アジア太平洋地域
• その他

第7章 企業プロファイル

• ABBOTT LABORATORIES INC
• ALERE INC.
• ASTRAZENECA LTD
• BAYER AG
• BECTON, DICKINSON AND COMPANY
• BOEHRINGER INGELHEIM
• DEXCOM INC
• ELI LILY AND CO.
• F. HOFFMANN-LA ROCHE LTD.
• GLAXOSMITHKLINE
• JOHNSON AND JOHNSON
• JOSLIN DIABETES CENTER
• LIFESCAN
• MEDTRONIC INC.
• MERCK & CO.
• NOVO-NORDISK
• PFIZER
• SANOFI
• SMITHS MEDICAL
• 武田薬品工業
• TANDEM DIABETES CARE

List of Tables

• TABLE # 1 GLOBAL TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY,2017-2023($ MILLIONS)
• TABLE # 2 GLOBAL TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2017-2023($ MILLION)
• TABLE # 3 GLOBAL RAPID-ACTING MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLIONS)
• TABLE # 4 GLOBAL LONG-ACTING MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLIONS)
• TABLE # 5 GLOBAL PREMIX ANALOGS MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLIONS)
• TABLE # 6 GLOBAL TYPE1 DIABETES MARKET AND RESEARCH ANALYSIS BY DRUG CLASS, 2017-2023 ($ MILLIONS)
• TABLE # 7 GLOBAL INSULIN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
• TABLE # 8 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
• TABLE # 9 GLOBAL TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICES, 2017-2023 ($ MILLIONS)
• TABLE # 10 GLOBAL INSULIN PUMPS MARKET RESEARCH AND ANALYSIS, 2017-20223 ($ MILLIONS)
• TABLE # 11 GLOBAL INSULIN PEN MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLIONS)
• TABLE # 12 GLOBAL BLOOD GLUCOSE MONITORS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
• TABLE # 13 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLIONS)
• TABLE # 14 NORTH AMERICA TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2017-2023($MILLIONS)
• TABLE # 15 NORTH AMERICA TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2017-2023($MILLIONS)
• TABLE # 16 NORTH AMERICA TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICES, 2017-2023($MILLIONS)
• TABLE # 17 EUROPE TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2017-2023($MILLIONS)
• TABLE # 18 EUROPE TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2017-2023($MILLIONS)
• TABLE # 19 EUROPE TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICES, 2017-2023($MILLIONS)
• TABLE # 20 ASIA PACIFIC TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY INSULIN ANALOG, 2017-2023($MILLIONS)
• TABLE # 21 ASIA PACIFIC TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2017-2023($MILLIONS)
• TABLE # 22 ASIA PACIFIC TYPE1 DIABETES MARKET RESEARCH AND ANALYSIS BY DEVICES, 2017-2023($MILLIONS)

List of Figures

• FIGURE # 1 GLOBAL TYPE1 DIABETES MARKET SHARE BY INSULIN ANALOG 2017 VS 2023, (IN %)
• FIGURE # 2 GLOBAL TYPE1 DIABETES MARKET SHARE BY DRUG CLASS 2017 VS 2023, (IN %)
• FIGURE # 3 GLOBAL TYPE1 DIABETES MARKET SHARE BY DEVICES 2017 VS 2023, (IN %)
• FIGURE # 4 GLOBAL TYPE1 DIABETES MARKET SHARE BY GEOGRAPHY 2017 VS 2023, (IN %)
• FIGURE # 5 NORTH AMERICAN TYPE1 DIABETES MARKET SIZE,2017-2023($MILLIONS)
• FIGURE # 6 US TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 7 CANADA TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 8 EUROPEAN TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 9 UK TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 10 FRANCE TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 11 GERMANY TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 12 ITALY TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 13 SPAIN TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 14 ROE TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 15 ASIA PACIFIC TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 16 INDIA TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 17 CHINA TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 18 JAPAN TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 19 ROAPAC TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)
• FIGURE # 20 REST OF THE WORLD TYPE1 DIABETES MARKET SIZE, 2017-2023($MILLIONS)

The global type1 diabetes market is expected to grow modestly during the forecast period owing to growing incidence and prevalence of diabetes and cohesive government policies. Type1 diabetes is a serious, chronic condition that is caused when insulin is not created within the body, making the glucose level too high. It is the condition when cells that make insulin are attacked and destroyed by the body, it causes type1 diabetes. Out of all the diabetic patients, only 5% have type1 diabetes. The growth of the market is also dependent on technological advancement in the insulin delivery and rising demand for minimally invasive and non-invasive insulin delivery.

The other factors contributing to the growth of the market include cohesive government policies, initiatives and programs for the type1 diabetes. Apart from this, increasing chronic diseases associated with diabetes are contributing significantly to the growth of the market. However, certain factors such as high cost of the diagnosis and treatment therapies for diabetes may hamper the growth of global type1 diabetes market. Geographically, the global type1 diabetes market has been divided into North America, Europe, Asia Pacific and Rest of the World. North America dominates the global type1 diabetes market due to technological advancements and supportive government initiatives in this region. APAC is anticipated to be the most emerging market due to increasing number of diabetics due to obesity, geriatric population, and changing lifestyles of the people.

The companies contributing to the growth of global type1 market includes Abbott Laboratories, Bayer AG, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd., Merck & C0., and Pfizer Inc. Majority of the players are adopting various strategies such as mergers and acquisitions or entering into strategic alliance with other major players from the market in order to gain a competitive edge over others and enhance their presence.

Research Methodology

The market study of type1 diabetes market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The OMR team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. The numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analysts to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts to get first-hand information. Primary research brings authenticity to our reports.

Secondary sources include:

Financial reports of companies involved in the market

Whitepapers, research-papers and news blogs

Company websites and their product catalogue

The report is intended for hospitals, diagnostic centers, Laboratories, universities, private and government organizations for the overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, and intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models such as PEST analysis delivering insights into the market for better business decisions.

Market Segmentation:

Global type1 diabetes market by insulin analog

Global type1 diabetes market by drug class

Global type1 diabetes market by devices

The Report covers:

Comprehensive research methodology of Global Type1 Diabetes Market.

This report also includes detailed and extensive market overview with Analyst insights & key market trends.

Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the Global Type1 Diabetes Market.

Insights about market determinants which are stimulating the Global Type1 Diabetes Market.

Detailed and extensive market segments with regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

CHAPTER 1. REPORT SUMMARY

• 1.1. RESEARCH METHODS AND TOOLS
• 1.2. MARKET BREAKDOWN
• 1.2.1. BY SEGMENTS
• 1.2.2. BY GEOGRAPHY
• 1.2.3. BY STAKEHOLDERS

CHAPTER 2. MARKET OVERVIEW AND INSIGHTS

• 2.1. DEFINITION
• 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
• 2.2.1. KEY FINDINGS
• 2.2.2. RECOMMENDATION
• 2.2.3. CONCLUSION
• 2.3. REGULATIONS
• 2.3.1. UNITED STATES
• 2.3.2. EUROPEAN UNION
• 2.3.3. CHINA
• 2.3.4. INDIA
• 2.3.5. REST OF THE WORLD

CHAPTER 3. MARKET DETERMINANT

• 3.1. MOTIVATORS
• 3.1.1. INCREASING CHRONIC DISEASES ASSOCIATED WITH DIABETES
• 3.1.2. RISING DEMAND FOR NON-INVASIVE MONITORING DEVICES
• 3.1.3. GROWING WEARABLE DEVICES FOR MONITORING
• 3.1.4. INCREASING GOVERNMENT INITIATIVES
• 3.2. RESTRAINTS
• 3.2.1. HIGH COST OF DIAGNOSIS AND TREATMENT
• 3.2.2. LACK OF AWARENESS IN EMERGING ECONOMIES
• 3.3. OPPORTUNITIES
• 3.3.1. RISING DIABETES PATIENTS IN APAC REGION
• 3.3.2. INCREASING DEVELOPMENT OF PIPELINE PRODUCTS
• 3.3.3. DEVELOPMENT OF MINIMALLY INVASIVE AND NON-INVASIVE MONITORING
• 3.3.4. DEVELOPMENT OF ARTIFICIAL PANCREAS

CHAPTER 4. MARKET SEGMENTATION

• 4.1. GLOBAL TYPE1 DIABETES MARKET BY INSULIN ANALOG
• 4.1.1. RAPID-ACTING
• 4.1.2. LONG-ACTING
• 4.1.3. PREMIX
• 4.2. GLOBAL TYPE1 DIABETES MARKET BY DRUG CLASS
• 4.2.1. INSULIN
• 4.2.2. OTHERS
• 4.3. GLOBAL TYPE1 DIABETES MARKET BY DEVICES
• 4.3.1. INSULIN PUMPS
• 4.3.2. INSULIN PEN
• 4.3.3. BLOOD GLUCOSE METERS
• 4.3.4. OTHERS

CHAPTER 5. COMPETITIVE LANDSCAPE

• 5.1. STRATEGY ANALYSIS
• 5.2. KEY COMPANY ANALYSIS

CHAPTER 6. REGIONAL ANALYSIS

• 6.1. NORTH AMERICA
• 6.1.1. UNITED STATES
• 6.1.2. CANADA
• 6.2. EUROPE
• 6.2.1. UNITED KINGDOM
• 6.2.2. FRANCE
• 6.2.3. GERMANY
• 6.2.4. ITALY
• 6.2.5. SPAIN
• 6.2.6. REST OF EUROPE
• 6.3. ASIA PACIFIC
• 6.3.1. INDIA
• 6.3.2. CHINA
• 6.3.3. JAPAN
• 6.4. REST OF THE WORLD

CHAPTER 7. COMPANY PROFILES

• 7.1. ABBOTT LABORATORIES INC
• 7.2. ALERE INC.
• 7.3. ASTRAZENECA LTD
• 7.4. BAYER AG
• 7.5. BECTON, DICKINSON AND COMPANY
• 7.6. BOEHRINGER INGELHEIM
• 7.7. DEXCOM INC
• 7.8. ELI LILY AND CO.
• 7.9. F. HOFFMANN-LA ROCHE LTD.
• 7.10. GLAXOSMITHKLINE
• 7.11. JOHNSON AND JOHNSON
• 7.12. JOSLIN DIABETES CENTER
• 7.13. LIFESCAN
• 7.14. MEDTRONIC INC.
• 7.15. MERCK & CO.
• 7.16. NOVO-NORDISK
• 7.17. PFIZER
• 7.18. SANOFI
• 7.19. SMITHS MEDICAL
• 7.20. TAKEDA PHARMACEUTICAL LTD.
• 7.21. TANDEM DIABETES CARE